The National Institute for Health and Care Excellence (NICE) in the United Kingdom has recommended the drug talazoparib (Talzenna by Pfizer) in combination with enzalutamide (Xtandi) for adult patients with metastatic prostate cancer.[1][2] This medication is indicated for patients who are not suitable for chemotherapy and who cannot take or tolerate abiraterone with prednisolone.[2] It is a daily pill that can be taken at home, increasing patient convenience and reducing the burden on the NHS.[1][2] Talazoparib blocks an enzyme that repairs damaged DNA in cancer cells, killing them.[2] Clinical trials showed that patients on combination therapy lived an average of 45.8 months compared to 37 months on enzalutamide alone, an increase of almost 9 months.[2] Time without cancer worsening increased to 33.1 months versus 19.5 months, more than a year.[2] Around 2,400 people in England are eligible for this treatment, which is available on the NHS from today at a discounted price under a commercial agreement.[2]